Clinical Trials Browser

INDUSTRY × Breast Neoplasms × bivatuzumab mertansine × Clear all

NCT02254005 2023-10-24

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02254031 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms